Skip to main navigation menu Skip to main content Skip to site footer

Narrative Review

Vol. 11 No. 1 (2008)

Hepatic Fibrosis: Novel Strategies in Detection and Therapy

  • Venkataramana Bhat
  • Mamatha Bhat
November 1, 2020




  1. Gressner, AM. The cell biology of liver fibrogenesis - an imbalance of proliferation, grow th arrest and apoptosis of myofibroblasts. Cell Tissue Res 1998; 292:447.
  2. Poynard T, Mathurin, P, Lai, CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257.
  3. Zou, S., Tepper, M. & Giulivi, A. (2000). Current status of hepatitis C in Canada. Canadian Journal of Public Health, 91, 1, S10-S15.
  4. Bloodborne Pathogens Section, Blood Safety Surveillance and Health Care Acquired Infections Division, Health Canada, 2003
  5. Gaiani S, Gramantieri L, Venturoli N et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and
  6. percutaneous liver biopsy. J Hepatol 1997; 27:979-985.
  7. Ferral H, Male R, Cardiel R, et al. Cirrhosis: Diagnosis by liver surface analysis with high-frequency ultrasound. Abdominal
  8. Imaging 1992;17: 1432-0509
  9. Zheng R, Wang Q, Lu M, et al. Liver fibrosis in chronic viral
  10. hepatitis: an ultrasonographic study. World J Gastroenterol.
  11. ; 9:2484-2489.
  12. Fidler, J.L. & Stark, D.D. (1999). Magnetic resonance imaging
  13. of the upper abdomen. In J. Traveras & J. Ferrucci (Eds.), Radiology: diagnosis - imaging - intervention, vol. 4 (pp. 1-17). Pennsylvania: J.B. Lippincott Company.
  14. Pagliaro L, Rinaldi F, Craxi A, et al. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. Dig Dis Sci. 1983; 28:39-43.
  15. P. Bedossa, T. Poynard and The METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C, Hepatology 1996; 24:289–293
  16. Garcia-Tsao G. Boyer JL. Outpatient liver biopsy: how safe is it? Ann Intern Med 1993; 118: 150-3.
  17. de Franchis R, Dell’Era A. Non-invasive diagnosis of cirrhosis and the natural history of its complications. Best Practice & Research Clinical Gastroenterology 2007; 21:3-18.
  18. Sebastiani G, Vario A, Guido M et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686-693.
  19. Parkes J, Guha IN, Roderick P et al. Performance of serum marker panels for liver fibrosis in hepatitis C. J Hepatol 2006; 44: 462-474.
  20. Ziol M, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41:48-54.
  21. Ganne-Carrie N, Ziol M, de Ledinghen V, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006; 44:1511-1517.
  22. Castera L, Vergniol J. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350.
  23. Bonis PA, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2001; 344:452.
  24. Czaja A, Freese DK. Diagnosis and Treatment of Autoimmune hepatitis. Hepatology 2003; 473-496
  25. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884.
  26. Bruck R, Shirin H, Hershkoviz R, et al. Analysis of Arg-Gly- Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice. Gut 1997; 40:133.
  27. Kershenobich D, Vargas F, Garcia-Tsao G, et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988; 318:1709.
  28. Rodriguez L, Cerbon-Ambriz J, Munoz ML. Effects of colchicine and colchiceine in a biochemical model of liver injury and fibrosis. Arch Med Res 1998; 29:109.
  29. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426
  30. Jonsson JR, Clouston AD, Ando Y, et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001; 121:148.
  31. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5:226.
  32. Iimuro Y, Nishio T, Morimoto T, et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 2003; 124:445.
  33. Gressner AM. The cell biology of liver fibrogenesis - an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 1998; 292:447.


Download data is not yet available.